U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. The Lennox, International, Inc. - 606889 - 11/22/2022
  1. Warning Letters

CLOSEOUT LETTER

The Lennox, International, Inc. MARCS-CMS 606889 —

Delivery Method:
Via Email
Product:
Animal & Veterinary

Recipient:
Recipient Name
Mr. Akiva Boclin
Recipient Title
President
The Lennox, International, Inc.

100 Randolph Road
Somerset, NJ 08873-1384
United States

aboclin@lennoxrawhide.com
Issuing Office:
Division of Human and Animal Food Operations East II

United States


Dear Mr. Boclin,

The Food & Drug Administration has completed an evaluation of your firm’s corrective actions in response to our Warning Letter 606889, dated September 29, 2020. Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations, or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.


Jessica D. Weber
/S/
Compliance Officer
Baltimore District Office
Human & Animal Food East, Division 2
Office of Regulatory Affairs
U.S. Food and Drug Administration
T: 410-779-5407 
M: 443-280-1276
jessica.weber@fda.hhs.gov

Back to Top